{"id":"placebo-to-mepolizumab","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Injection site reaction"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Muscle pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IL-5 is a key cytokine in the development and activation of eosinophils, which are a type of white blood cell involved in allergic reactions and asthma. By inhibiting IL-5, mepolizumab reduces the production and survival of eosinophils, which can help to reduce inflammation and symptoms in patients with asthma and hypereosinophilic syndrome.","oneSentence":"Mepolizumab is an interleukin-5 (IL-5) inhibitor that blocks the action of IL-5, a cytokine involved in the production and survival of eosinophils.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:54.976Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe asthma with an eosinophilic phenotype"},{"name":"Eosinophilic granulomatosis with polyangiitis (EGPA)"}]},"trialDetails":[{"nctId":"NCT04157348","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-29","conditions":"Eosinophilic Granulomatous Vasculitis","enrollment":140},{"nctId":"NCT06572267","phase":"PHASE2","title":"Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-10-16","conditions":"Coronary Artery Disease","enrollment":18},{"nctId":"NCT05979051","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）","status":"RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2023-11-16","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":166},{"nctId":"NCT05263934","phase":"PHASE3","title":"Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-07-14","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":163},{"nctId":"NCT05030155","phase":"PHASE3","title":"Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-05-30","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":100},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT06824649","phase":"PHASE4","title":"Biologics in Chronic Rhinosinusitis With Nasal Polyposis","status":"NOT_YET_RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-03","conditions":"Chronic Sinusitis, Nasal Polyps","enrollment":504},{"nctId":"NCT03494881","phase":"EARLY_PHASE1","title":"Mepolizumab for the Treatment of Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-07-30","conditions":"Chronic Spontaneous Urticaria","enrollment":10},{"nctId":"NCT05902325","phase":"PHASE4","title":"Identifying Predictors Of Response To Mepolizumab In CRSwNP","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2023-10-03","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":36},{"nctId":"NCT04607005","phase":"PHASE3","title":"Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-04-22","conditions":"Nasal Polyps","enrollment":169},{"nctId":"NCT03562195","phase":"PHASE3","title":"A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-08-29","conditions":"Asthma","enrollment":300},{"nctId":"NCT04075331","phase":"PHASE2, PHASE3","title":"Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2020-09-07","conditions":"COPD, Eosinophilia","enrollment":238},{"nctId":"NCT04183192","phase":"PHASE1","title":"Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-02-17","conditions":"Healthy Subjects, Pharmacokinetics, Pharmacodynamics","enrollment":72},{"nctId":"NCT03298061","phase":"PHASE3","title":"Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-04-14","conditions":"Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis","enrollment":100},{"nctId":"NCT03656380","phase":"PHASE2","title":"Mepo for Eosinophilic Esophagitis (EoE) Study","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2019-03-20","conditions":"EoE, Eosinophilic Esophagitis","enrollment":66},{"nctId":"NCT03292588","phase":"PHASE2","title":"A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-11-07","conditions":"Asthma","enrollment":335},{"nctId":"NCT03085797","phase":"PHASE3","title":"Effect of Mepolizumab in Severe Bilateral Nasal Polyps","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-25","conditions":"Nasal Polyps","enrollment":414},{"nctId":"NCT01362244","phase":"PHASE2","title":"Mepolizumab in Nasal Polyposis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-12","conditions":"Nasal Polyps","enrollment":109},{"nctId":"NCT03306043","phase":"PHASE3","title":"A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-11-13","conditions":"Hypereosinophilic Syndrome","enrollment":102},{"nctId":"NCT00086658","phase":"PHASE3","title":"Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-03-23","conditions":"Hypereosinophilia, Hypereosinophilic Syndrome","enrollment":86},{"nctId":"NCT03610685","phase":"PHASE4","title":"Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2018-10-19","conditions":"Asthma","enrollment":33},{"nctId":"NCT03055195","phase":"PHASE2","title":"Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-03-21","conditions":"Dermatitis, Atopic","enrollment":34},{"nctId":"NCT02836496","phase":"PHASE3","title":"Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-03-07","conditions":"Hypereosinophilic Syndrome","enrollment":108},{"nctId":"NCT02555371","phase":"PHASE3","title":"Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-01-07","conditions":"Asthma","enrollment":306},{"nctId":"NCT02105948","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":837},{"nctId":"NCT02105961","phase":"PHASE3","title":"Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-24","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":674},{"nctId":"NCT02281318","phase":"PHASE3","title":"Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-12-11","conditions":"Asthma","enrollment":556},{"nctId":"NCT02020889","phase":"PHASE3","title":"A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-05","conditions":"Churg-Strauss Syndrome","enrollment":136},{"nctId":"NCT01000506","phase":"PHASE2","title":"Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-01","conditions":"Asthma","enrollment":621},{"nctId":"NCT02594332","phase":"PHASE3","title":"Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study","status":"TERMINATED","sponsor":"Johannes Gutenberg University Mainz","startDate":"2015-11-17","conditions":"Asthma","enrollment":29},{"nctId":"NCT01471327","phase":"PHASE1","title":"Japanese Phase 1 Study of Mepolizumab","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-08-09","conditions":"Asthma","enrollment":35},{"nctId":"NCT01691508","phase":"PHASE3","title":"Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10","conditions":"Asthma","enrollment":135},{"nctId":"NCT00274703","phase":"PHASE2","title":"An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12","conditions":"Oesophagitis, Eosinophilic","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":208,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Mepolizumab","genericName":"Placebo to Mepolizumab","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Biologic","firstApprovalDate":"","aiSummary":"Mepolizumab is an interleukin-5 (IL-5) inhibitor that blocks the action of IL-5, a cytokine involved in the production and survival of eosinophils. Used for Severe asthma with an eosinophilic phenotype, Eosinophilic granulomatosis with polyangiitis (EGPA).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}